GBA1 and neurodegenerative disease: Glucocerebrosidase (GCase) activity was investigated in the proband as reported, and was found to be significantly reduced (4.72 nmol/h/mg) compared to healthy controls as well as patients affected by neurodegenerative diseases (range in healthy controls: 7.7–17.47 nmol/h/mg) [6–8].